Skip to main content
AACR Project GENIE v19.0 · 21,017 myeloid samples Panel-adjusted Fisher's exact with Benjamini-Hochberg FDR N=1 case study · Not clinical guidance

EZH2 V662A Discovery

Novel unreported variant, SET domain loss-of-function, PRC2 sixth axis

Literature Hits Novel
0
0 for 'EZH2 V662A' or 'EZH2 V662' in Semantic Scholar; PubMed also 0 (rechecked 2 Nov 2026) i
EVE Score Uncertain
0.7825
Evolutionary model, Frazer et al. Nature 2021. Label at EVE's class25 threshold. i
AlphaMissense Likely pathogenic
0.9984
DeepMind proteome-wide missense predictor (its own class label) i
ACMG Points Likely Pathogenic
9
Bayesian point system (Likely Pathogenic 6-9, Pathogenic 10+), 9 achieved; research classification, ClinVar: VUS i
GENIE Carriers Absent
0 / 20,739
Not observed in the 20,739 GENIE v19.0 myeloid samples whose panel covers EZH2 i

Novel Discovery

EZH2 V662A has never been described in the scientific literature. A search of PubMed and Semantic Scholar returns zero results for "EZH2 V662A" or "EZH2 V662." Among the 314 EZH2 papers retrieved for this search, none report this specific variant. ClinVar has a single record with no publications (below).

The variant is absent from gnomAD v4 (0 alleles across ~1.6 million alleles) and absent from GENIE v19.0 (0 carriers among the 20,739 myeloid samples whose panel covers EZH2, see the denominator table).

ClinVar holds one record for this variant: VCV003373649.1, submitted by GeneDx and classified as a variant of uncertain significance (germline, condition not provided), last evaluated March 2024. It carries no functional evidence, no disease context and no supporting publications. This project has not submitted the variant to ClinVar.

The variant has never been described in the indexed literature and has never been characterised in a somatic or myeloid context, in a gene that has been studied extensively for over 15 years in myeloid malignancies.

Computational Pathogenicity

ModelScoreClassificationReference
EVE0.7825Uncertain (at EVE's class25 threshold)Frazer et al. Nature 2021
AlphaMissense0.9984Likely pathogenicCheng et al. Science 2023
CADD28.1Deleterious (threshold 25.3)Schubach et al. Nucleic Acids Res 2024 (v1.7); threshold: Pejaver et al. Am J Hum Genet 2022
REVEL0.781Pathogenic (threshold 0.644)Ioannidis et al. Am J Hum Genet 2016; threshold: Pejaver et al. 2022
ESM-2 LLR-2.966PP3 SupportingLin et al. Science 2023
SIFT0.0Deleterious (low confidence)Ng & Henikoff 2003
PolyPhen-20.992Probably damagingAdzhubei et al. 2010
6 of 7 independent computational models classify EZH2 V662A as pathogenic or damaging, giving PP3_Strong. EVE does not: EVE returns 0.7825, which its own class25 calibration (25th/75th percentile ClinVar calibration (recommended)) labels Uncertain. CADD and REVEL are the Ensembl VEP CADD v1.7 values.

SET Domain Loss-of-Function

V662A (NP_004447.2 numbering; V657 in UniProt Q15910 numbering) falls within the catalytic SET domain (residues 612 to 727, UniProt Q15910) of EZH2, the enzymatic subunit of the Polycomb Repressive Complex 2 (PRC2). This domain is responsible for trimethylation of histone H3 at lysine 27 (H3K27me3), a critical epigenetic silencing mark.

Chase et al. 10
[10] A 2020
Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020)
and the same group's earlier in vitro work showed loss or greatly reduced H3K27 methylation for the SET/CXC missense mutants they tested (C576W, R690C, Y731D). V662 itself was not tested, so loss of function for V662A is inferred from its position in the SET domain, not measured. This is the opposite mechanism from lymphoid malignancies (DLBCL), where EZH2 gain-of-function mutations at Y646 increase H3K27me3. The tissue-specific directionality is critical for therapeutic decisions.

Ernst et al. 9
[9] T 2010
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010)
first described EZH2 inactivating mutations in myeloid disorders (2010, 1,195 citations). The myeloid context is now well established: EZH2 acts as a tumor suppressor, and loss-of-function mutations contribute to disease through derepression of Polycomb target genes.

Tazemetostat: CONTRAINDICATED

Tazemetostat (Tazverik) is an EZH2 inhibitor that held FDA accelerated approval in relapsed or refractory follicular lymphoma (EZH2-mutant, or any EZH2 status without other options) and in epithelioid sarcoma, a tumour driven by SMARCB1/INI1 loss, not EZH2 mutation. It works by inhibiting EZH2 enzymatic activity.

EZH2 V662A is inferred to be a loss-of-function mutation. Tazemetostat inhibits the very activity that is already lost. Administering it would further reduce residual H3K27me3, potentially worsening the epigenetic dysregulation.

This is not a theoretical concern. Ipsen voluntarily withdrew tazemetostat in all indications from all its markets on March 9, 2026, after hematologic second cancers (mostly MDS and AML) emerged in the SYMPHONY-1 trial, and the distinction between gain-of-function (lymphoid) and loss-of-function (myeloid) EZH2 mutations is fundamental to the biology 10
[10] A 2020
Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020)
.

Clinical implication: Any clinician seeing "EZH2 mutation" in a myeloid patient must verify the functional consequence before considering EZH2-targeted therapy. The mutation name alone is insufficient; the mechanism (GoF vs LoF) determines whether therapy helps or harms.

Research classification: Likely Pathogenic (ClinVar: VUS)

EZH2 V662A was initially classified as a Variant of Uncertain Significance (VUS) due to the absence of direct functional assay data (PS3 at Supporting level only, no definitive functional study of V662A specifically).

Re-running the ACMG aggregation against the current evidence files gives Likely Pathogenic at 9 Bayesian points (Likely Pathogenic from 6, Pathogenic from 10). This is a research classification; the public ClinVar record remains a VUS. The evidence lines it draws on, and the points each one contributes, are listed in the table below.

The computational evidence line is PP3_Strong, on 6/7 concordant predictors: AlphaMissense 0.9984, CADD 28.1, REVEL 0.781, ESM-2 LLR -2.966, SIFT and PolyPhen-2. EVE is the dissenting tool at 0.7825, which its own class25 calibration labels Uncertain. In-silico evidence is capped at Strong (ClinGen SVI, Pejaver et al. 2022), so the computational line adds 4 points and does not depend on the EVE vote.

With this classification the patient profile is 4 confirmed drivers plus EZH2 V662A as Likely Pathogenic (research classification, without a functional assay of V662A itself).
ACMG CriterionStrengthPointsEvidence
PP3Strong46/7 pathogenic: AlphaMissense=0.9984 (PP3_Strong), CADD=28.1, REVEL=0.781, ESM-2 LLR=-2.966, EVE=0.7825 (Uncertain), SIFT=0.0, PolyPhen-2=0.992 [capped at Strong: ClinGen SVI, Pejaver et al. 2022, Am J Hum Genet 109:2163-2177, PMID 36413997]
PM1Moderate2Catalytic SET domain (612-727). Critical for H3K27 methyltransferase activity.
PS3Supporting1V662A in catalytic SET domain (612-727). Loss-of-function reducing H3K27me3. EZH2 LOF established as tumor suppressor in myeloid lineage. Ernst 2010, Nikoloski 2010. No direct functional assay for V662A specifically (PS3 at Supporting level).
PM2Supporting1Absent from gnomAD v4 (AC=0). Completely absent from gnomAD (0 alleles across exomes + genomes)
PM5Supporting1Other missense variants in the EZH2 SET domain (e.g., Y646, A682, A692) are established as pathogenic in lymphoid malignancies (gain-of-function). In myeloid context, EZH2 LOF missense across SET domain are recurrent.
Total9Likely Pathogenic (threshold: 10)
ACMG/AMP Bayesian point system (Tavtigian et al. Hum Mutat 2020). Richards et al. Genet Med 2015. Rows are read from acmg_aggregation.json as regenerated on 2026-11-03; no value on this page is entered by hand.

PRC2: The 6th Convergence Axis

With EZH2 V662A classified Likely Pathogenic, the patient's mutation profile spans 6 biological convergence axes, not 5:

1. DNA methylation (DNMT3A R882H)
2. Metabolic (IDH2 R140Q, 2-HG production)
3. PP2A tumor suppression (SETBP1 G870S)
4. RAS-MAPK signaling (PTPN11 E76Q)
5. Cytogenetic (monosomy 7)
6. Chromatin remodeling / PRC2 (EZH2 V662A)

The PRC2 axis is mechanistically distinct from the DNA methylation axis (DNMT3A) and the metabolic axis (IDH2). While all three affect the epigenetic landscape, they operate through independent biochemical pathways: CpG methylation, histone H3K27 trimethylation, and alpha-ketoglutarate-dependent dioxygenase inhibition, respectively.

This 6-axis convergence on a single patient is, to our knowledge, unprecedented in the myeloid genomics literature.

EZH2 Literature Landscape

QueryHits
EZH2 V662A0
EZH2 V6620
EZH2 loss-of-function myeloid100 (capped)
EZH2 mutation MDS AML100 (capped)
PRC2 myeloid malignancy77
EZH2 monosomy 761
EZH2 SET domain missense22
Semantic Scholar query results, retrieval capped at 100 papers per query, so "(capped)" means at least 100. 314 unique papers retrieved across all EZH2-related queries.
The EZH2 literature is extensive (this capped search alone retrieved 314 unique papers), with landmark studies including Ernst et al. 9
[9] T 2010
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010)
(1,195 citations, first description of EZH2 inactivation in myeloid disorders) and Chase et al. 10
[10] A 2020
Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020)
(SET domain LoF mechanism).

Ball et al. 11
[11] S 2023
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: a large single institution analysis of 1774 patients. Leuk Res (2023)
showed that, within EZH2-mutant MDS, concurrent chromosome 7 abnormalities were associated with significantly worse overall survival (median 20.8 vs 35.5 months, p=0.002), the shortest median reported in that abstract. This patient has both: EZH2 V662A on monosomy 7, placing them in that subgroup.

Clinical Implications

Classifying EZH2 V662A as Likely Pathogenic has three immediate clinical consequences:

1. Tazemetostat contraindication. Any EZH2-targeted therapy designed to inhibit EZH2 activity is contraindicated. The enzymatic activity is already lost.

2. Prognostic impact. EZH2 LoF mutations with chromosome 7 abnormalities carry inferior survival 11
[11] S 2023
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: a large single institution analysis of 1774 patients. Leuk Res (2023)
. In that cohort this subgroup had the shortest reported median survival among EZH2-mutant MDS (20.8 months).

3. Profile rarity. With EZH2 V662A counted as the fifth variant, 0 of 8,655 GENIE patients carry the profile, which bounds its frequency below 1 in 2,889 (95%, exact binomial); no point estimate exists. The profile was already unprecedented as a quadruple; as a quintuple it is genuinely unknown territory for prognostic modeling.

The classification rests on in silico evidence (PP3_Strong) rather than direct functional assay data. No ClinVar submission has been made; the public record for this variant remains VCV003373649.1, GeneDx's germline VUS of March 2024.
References
  1. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010). PubMed
  2. Chase A, Score J, Lin F, et al. Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020). PubMed
  3. Ball S, Aguirre LE, Jain AG, et al. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome. Leuk Res (2023). PubMed
  4. Frazer J, Notin P, Dias M, et al. Disease variant prediction with deep generative models of evolutionary data. Nature (2021). PubMed
  5. Cheng J, Novati G, Pan J, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science (2023). PubMed
  6. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants. Genet Med (2015). PubMed
  7. Tavtigian SV, Harrison SM, Boucher KM, Biesecker LG. Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. Hum Mutat (2020). PubMed